Lynn Morris to Vaccination
This is a "connection" page, showing publications Lynn Morris has written about Vaccination.
Connection Strength
0,303
-
High titer HIV-1 V3-specific antibodies with broad reactivity but low neutralizing potency in acute infection and following vaccination. Virology. 2009 May 10; 387(2):414-26.
Score: 0,068
-
Differential V2-directed antibody responses in non-human primates infected with SHIVs or immunized with diverse HIV vaccines. Nat Commun. 2022 02 16; 13(1):903.
Score: 0,042
-
Antibody and cellular responses to HIV vaccine regimens with DNA plasmid as compared with ALVAC priming: An analysis of two randomized controlled trials. PLoS Med. 2020 05; 17(5):e1003117.
Score: 0,037
-
Immune correlates of the Thai RV144 HIV vaccine regimen in South Africa. Sci Transl Med. 2019 09 18; 11(510).
Score: 0,035
-
Select gp120 V2 domain specific antibodies derived from HIV and SIV infection and vaccination inhibit gp120 binding to a4ß7. PLoS Pathog. 2018 08; 14(8):e1007278.
Score: 0,033
-
Subtype C ALVAC-HIV and bivalent subtype C gp120/MF59 HIV-1 vaccine in low-risk, HIV-uninfected, South African adults: a phase 1/2 trial. Lancet HIV. 2018 07; 5(7):e366-e378.
Score: 0,032
-
Features of Recently Transmitted HIV-1 Clade C Viruses that Impact Antibody Recognition: Implications for Active and Passive Immunization. PLoS Pathog. 2016 07; 12(7):e1005742.
Score: 0,028
-
Subtype C gp140 Vaccine Boosts Immune Responses Primed by the South African AIDS Vaccine Initiative DNA-C2 and MVA-C HIV Vaccines after More than a 2-Year Gap. Clin Vaccine Immunol. 2016 06; 23(6):496-506.
Score: 0,028